Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Novartis AG (ADR) (NVS) And Pfizer Inc. (PFE) Are In A Race To Gain Favor In Breast Cancer

Novartis AG (ADR) (NYSE:NVS) CDK4/6 breast cancer drug remains on track with Pfizer Inc. (NYSE:PFE)‘s Ibrance. The pharma giant has already obtained a regulatory pathway for its LEE011 from the FDA after going through the hurdle of priority review.

The medication, which is in the line-up for the treatment of postmenopausal women who have advanced breast cancer, has also been acknowledged by the European Medicines Agency (EMA) for re-examination. This is a clear indication that the company is moving closer to a potential leapfrogging of Ibrance.

From its study results, presented at the ESMO 2016 Congress last month, Novartis AG (ADR) (NYSE:NVS) explains that the combo of LEE011 as well as the standard hormone therapy Femara has close to 44% rate of reducing the risk of disease progression or death. This may not be the case with Femara alone.

Pfizer PFE pharmaceutical stock

pio3 / Shutterstock.com

Novartis looks set to be second to market

LEE011 was tested in women with tumors categorized as hormone receptor positive. If all goes well, the Swiss company will take second position in a market dominated by Pfizer Inc. (NYSE:PFE).

Confident about the company’s performance, the head of Novartis’s oncology business, Bruno Strigini stated, “Priority Review allows a shorter review period compared with FDA standard review in the U.S., helping us to potentially bring LEE011 plus letrozole to patients more quickly”

Follow Novartis A G (NYSE:NVS)
Trade (NYSE:NVS) Now!

It is not all about LEE011 for Novartis

The success of Novartis’ cancer drug is perhaps the beginning of brighter future for the company. At the very least, and for purposes of regulatory procedures, Novartis will be offering additional monitoring to patients using the med without necessarily having to put any physician burden on them.

However, Credit Suisse analysts feel that this safety responsibility may not obtain broader acceptance. The concerns might suprise Novartis AG (ADR) (NYSE:NVS), according to Credit Suisse’s Vamil Divan, who says that the company may even fall behind Eli Lilly and Co (NYSE:LLY), which is laying out its strategy with its rival abemaciclib. Meanwhile, Novartis’ closed its last trading session at $71.35, for an increase of $0.3 or 0.46%.

Follow Pfizer Inc (NYSE:PFE)
Trade (NYSE:PFE) Now!

Note: This article is written by Andy Parker and originally published at Market Exclusive.

Loading Comments...